News | Stereotactic Body Radiation Therapy (SBRT) | March 13, 2020

X1 machine rotates up to 60 times faster than other linear accelerators for precise dose delivery to tumors

Reflexion eceived marketing clearance from the U.S. Food & Drug Administration (FDA) for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT) for its RefleXion X1 machine

March 13, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy (BgRT) to treat all stages of cancer today announced it has received marketing clearance from the U.S. Food & Drug Administration (FDA) for stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT) for its RefleXion X1 machine.

“We are at the forefront of an enormous change in expanding the use of radiotherapy from a treatment solely for early-stage cancer patients to an entirely new group of patients who need it most, those with advanced stage cancer,” said Todd Powell, CEO and president of RefleXion. “This initial marketing clearance of our RefleXion X1 machine is a steppingstone on the path to our goal of providing BgRT as a novel treatment modality that will expand the overall radiotherapy market significantly.

“We have been preparing for commercial operations in the brand new factory we opened last year and expect to begin machine shipments within the next quarter,” continued Powell.

The RefleXion X1 is the only machine that combines high quality computed tomography (CT) imaging, known as fan-beam CT, with a linear accelerator to reduce motion artifacts that can inhibit accurate targeting of the radiation dose to a patient’s tumor. Its groundbreaking design rotates up to 60 times faster than other linear accelerators and modulates dose delivery from 100 points per beam station. These combined improvements may reduce the side effects of radiotherapy by allowing radiation oncologists to better localize the tumor, reduce patient setup errors and precisely deliver dose to complex tumor targets while avoiding nearby normal structures.

"Transitioning this company from a research effort to what is, as of today, a commercial entity has been a thrilling 10-year journey,” said Sam Mazin, Ph.D., founder and CTO of RefleXion. “Along the way, RefleXion has become an organization supported by dedicated and brilliant people in every corner, including our clinical partners. We will celebrate this milestone and then quickly turn our sights to bringing our biology-guided radiotherapy to market.”

BgRT, a novel treatment modality under development, uses the biological signature of a tumor to characterize its movement and to deliver a precisely tracked therapeutic radiation dose to the tumor. The RefleXion X1 machine with BgRT is designed to overcome the technical limitations that currently restrict radiotherapy to one or two tumors. Once developed, RefleXion will scale BgRT to treat all visible tumors, even those that move rapidly due to involuntary processes such as breathing or digestion, in the same treatment session.

For more information:

Related content on stereotactic body radiotherapy:

VIDEO: Biologically Guided Radiation Therapy Using Real-time PET Imaging

VIDEO: Editor's Choice of the Most Innovative Radiation Oncology Tech at ASTRO 2018

Top Technology Trends at ASTRO 2018

Related Content

News | Prostate Cancer

September 22, 2023 — According to an accepted manuscript published in the American Journal of Roentgenology (AJR) ...

Time September 22, 2023
Feature | Radiation Oncology

The radiation oncology community lost a leader this past summer, with the passing of Jay Loeffler, MD, FACR, FASTRO. He ...

Time September 21, 2023
Feature | Proton Therapy | By Christine Book

An overview of significant developments in proton therapy, over just the past six months, reinforces the pace of ...

Time September 21, 2023
News | Radiation Therapy

September 20, 2023 — RefleXion Medical, Inc., a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a ...

Time September 20, 2023
News | Ultrasound Imaging

September 8, 2023 — When diagnosing and treating cancer patients, the dynamics of blood flow to and from a suspected ...

Time September 08, 2023
News | ASTRO

September 7, 2023 — American Society for Radiation Oncology (ASTRO) President Jeff Michalski, MD, MBA, FASTRO, will join ...

Time September 07, 2023
Feature | Radiology Business | By Melinda Taschetta-Millane

As we wind down the summer months, ITN takes a look at the Top 10 most-read pieces of content from ...

Time August 31, 2023
News | Radiation Therapy

August 30, 2023 — A published study by researchers at the University of Cincinnati Cancer Center and Cincinnati Children ...

Time August 30, 2023
News | Radiopharmaceuticals and Tracers

August 28, 2023 — TerraPower Isotopes and PanTera, the Belgian joint venture created by SCK CEN and IBA, announced that ...

Time August 28, 2023
Feature | Radiology Education | By Melinda Taschetta-Millane

ITN’s award-winning editorial team delivers industry trends and technology information to the professionals who make ...

Time August 28, 2023
Subscribe Now